Literature DB >> 18725317

Interleukin-23: immunological roles and clinical implications.

Zi Yan Tan1, Kenneth W Bealgey, Yong Fang, Yang Ming Gong, Shisan Bao.   

Abstract

Increasing evidence has revealed the importance of IL-23, which closely resembles IL-12 both structurally and immunologically, in linking innate and adaptive immunity. IL-23, produced by activated type 1 macrophages and dendritic cells (DC), possesses unique roles in the differentiation and expansion of memory T cells. IL-23 has been associated with several inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD) and Helicobacter pylori associated gastritis, mainly due to its capacity to induce a strong Th1 type immune response. IL-23 is also associated with Th17 responses and the cytokine produced by the antigen presenting cells (APC), i.e. IL-12 vs IL-23 determines in part if a response is Th1 or Th17. Recent studies have also associated chronic inflammatory diseases such as IBD, psoriasis and myocardial infarction with polymorphisms of the IL-23 receptor complex. The current review focuses on the immunological role of IL-23 and possible therapeutic avenues for inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725317     DOI: 10.1016/j.biocel.2008.04.027

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  30 in total

1.  Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results.

Authors:  Tamer A Gheita; Iman I El Gazzar; Hussein S El-Fishawy; Mohamed A Aboul-Ezz; Sanaa A Kenawy
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

2.  Evaluation of Local and Systemic Levels of Interleukin-17, Interleukin-23, and Myeloperoxidase in Response to Periodontal Therapy in Patients with Generalized Aggressive Periodontitis.

Authors:  E Cifcibasi; C Koyuncuoglu; M Ciblak; S Badur; K Kasali; E Firatli; S Cintan
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 3.  Resolution of Crohn's disease.

Authors:  Heike Schmitt; Clemens Neufert; Markus F Neurath; Raja Atreya
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

Review 4.  Interleukin-23 as a potential therapeutic target for rheumatoid arthritis.

Authors:  Chao Rong; Wei Hu; Fan-rong Wu; Xiao-juan Cao; Fei-hu Chen
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

5.  Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy.

Authors:  Monika Słowińska; Agnieszka Kardynal; Olga Warszawik; Joanna Czuwara; Lidia Rudnicka
Journal:  J Dermatol Case Rep       Date:  2010-04-11

6.  Interaction between oral lichen planus and chronic periodontitis with Th17-associated cytokines in serum.

Authors:  Hui Wang; Zhenhua Luo; Lei Lei; Zheng Sun; Min Zhou; Hongxia Dan; Xin Zeng; Qianming Chen
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

Review 7.  IL-12 and related cytokines: function and regulatory implications in Candida albicans infection.

Authors:  Robert B Ashman; Dipti Vijayan; Christine A Wells
Journal:  Clin Dev Immunol       Date:  2010-11-01

8.  IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis.

Authors:  Seon-Yeong Lee; Young Ok Jung; Doo-Jin Kim; Chang-Min Kang; Young-Mee Moon; Yu-Jung Heo; Hye-Jwa Oh; Seong-Jeong Park; Se-Hwan Yang; Seung Ki Kwok; Ji-Hyeon Ju; Sung-Hwan Park; Young Chul Sung; Ho-Youn Kim; Mi-La Cho
Journal:  J Immunol       Date:  2015-08-31       Impact factor: 5.422

9.  T-helper 17 lymphocytes in ocular cicatricial pemphigoid.

Authors:  Alessandro Lambiase; Alessandra Micera; Flavio Mantelli; Caterina Moretti; Antonio Di Zazzo; Eleonora Perrella; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2009-07-28       Impact factor: 2.367

10.  Ustekinumab in the therapy of chronic plaque psoriasis.

Authors:  Jenna L O'Neill; Robert E Kalb
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.